Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report

High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20–40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the...

Full description

Saved in:

Bibliographic Details
Published in:	Opukholi zhenskoĭ reproduktivnoĭ sistemy Vol. 15; no. 1; pp. 73 - 77
Main Authors:	Andabekov, T. T., Rodina, M. K., Raskin, G. A., Cham, K. G., Rutkin, I. O.
Format:	Journal Article
Language:	English Russian
Published:	ABV-press 01-07-2019
Subjects:	dmmr endometrial carcinoma endometriоid adenocarcinoma immunotherapy msi-h pd-1 inhibitor pembrolizumab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20–40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the recent literature and the case of durable partial response on pembrolizumab immunotherapy in a patient with a metastatic endometrioid adenocarcinoma with MMR-deficiency progressed on 2 chemotherapy lines. Partial response was achieved after 6th course, treatment was stopped after 8th course. Patient is on follow-up without any anticancer treatment for 11 months. Partial response lasts for 13 months, with further reduction in tumor size. The treatment was well tolerated without adverse events.
ISSN:	1994-4098 1999-8627
DOI:	10.17650/1994-4098-2019-15-1-73-77